These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
354 related articles for article (PubMed ID: 18841277)
1. Factor IX: Insights from knock-out and genetically engineered mice. Monahan PE Thromb Haemost; 2008 Oct; 100(4):563-75. PubMed ID: 18841277 [TBL] [Abstract][Full Text] [Related]
2. FIX-Triple, a gain-of-function factor IX variant, improves haemostasis in mouse models without increased risk of thrombosis. Kao CY; Lin CN; Yu IS; Tao MH; Wu HL; Shi GY; Yang YL; Kao JT; Lin SW Thromb Haemost; 2010 Aug; 104(2):355-65. PubMed ID: 20539913 [TBL] [Abstract][Full Text] [Related]
3. Genetic modification of donor hepatocytes improves therapeutic efficacy for hemophilia B in mice. Wu YM; Kao CY; Huang YJ; Yu IS; Lee HS; Lai HS; Lee PH; Lin CN; Lin SW Cell Transplant; 2010; 19(9):1169-80. PubMed ID: 20412633 [TBL] [Abstract][Full Text] [Related]
4. [Establishment of a hemophilia B transgenic mouse model on the basis of coagulation factor IX gene knock-out mouse]. Che WL; He Y; Yao ZZ; Li J; Fu JL Yi Chuan Xue Bao; 2002 Jul; 29(7):594-8. PubMed ID: 12143307 [TBL] [Abstract][Full Text] [Related]
5. [Non-viral gene transfer results in therapeutic factor IX levels in haemophilia B mice]. Schüttrumpf J; Milanov P; Roth S; Seifried E; Tonn T Hamostaseologie; 2008 Oct; 28 Suppl 1():S92-5. PubMed ID: 18958345 [TBL] [Abstract][Full Text] [Related]
6. Therapeutic effects of hepatocyte transplantation on hemophilia B. Tatsumi K; Ohashi K; Shima M; Nakajima Y; Okano T; Yoshioka A Transplantation; 2008 Jul; 86(1):167-70. PubMed ID: 18622295 [TBL] [Abstract][Full Text] [Related]
7. Transgene expression levels and kinetics determine risk of humoral immune response modeled in factor IX knockout and missense mutant mice. Zhang TP; Jin DY; Wardrop RM; Gui T; Maile R; Frelinger JA; Stafford DW; Monahan PE Gene Ther; 2007 Mar; 14(5):429-40. PubMed ID: 17066096 [TBL] [Abstract][Full Text] [Related]
8. Therapeutic plasma concentrations of human factor IX in mice after gene delivery into the amniotic cavity: a model for the prenatal treatment of haemophilia B. Schneider H; Adebakin S; Themis M; Cook T; Douar AM; Pavirani A; Coutelle C J Gene Med; 1999; 1(6):424-32. PubMed ID: 10753068 [TBL] [Abstract][Full Text] [Related]
9. Genetic fusion to albumin improves the pharmacokinetic properties of factor IX. Metzner HJ; Weimer T; Kronthaler U; Lang W; Schulte S Thromb Haemost; 2009 Oct; 102(4):634-44. PubMed ID: 19806248 [TBL] [Abstract][Full Text] [Related]
10. Successful in vivo propagation of factor IX-producing hepatocytes in mice: potential for cell-based therapy in haemophilia B. Tatsumi K; Ohashi K; Kataoka M; Tateno C; Shibata M; Naka H; Shima M; Hisanaga M; Kanehiro H; Okano T; Yoshizato K; Nakajima Y; Yoshioka A Thromb Haemost; 2008 May; 99(5):883-91. PubMed ID: 18449417 [TBL] [Abstract][Full Text] [Related]
11. Sustained and therapeutic levels of human factor IX in hemophilia B mice implanted with microcapsules: key role of encapsulated cells. Wen J; Vargas AG; Ofosu FA; Hortelano G J Gene Med; 2006 Mar; 8(3):362-9. PubMed ID: 16311997 [TBL] [Abstract][Full Text] [Related]
12. An important role for the activation peptide domain in controlling factor IX levels in the blood of haemophilia B mice. Begbie ME; Mamdani A; Gataiance S; Eltringham-Smith LJ; Bhakta V; Hortelano G; Sheffield WP Thromb Haemost; 2005 Dec; 94(6):1138-47. PubMed ID: 16411385 [TBL] [Abstract][Full Text] [Related]
13. Permanent partial phenotypic correction and tolerance in a mouse model of hemophilia B by stem cell gene delivery of human factor IX. Bigger BW; Siapati EK; Mistry A; Waddington SN; Nivsarkar MS; Jacobs L; Perrett R; Holder MV; Ridler C; Kemball-Cook G; Ali RR; Forbes SJ; Coutelle C; Wright N; Alison M; Thrasher AJ; Bonnet D; Themis M Gene Ther; 2006 Jan; 13(2):117-26. PubMed ID: 16163377 [TBL] [Abstract][Full Text] [Related]
14. Engineering liver tissues under the kidney capsule site provides therapeutic effects to hemophilia B mice. Ohashi K; Tatsumi K; Utoh R; Takagi S; Shima M; Okano T Cell Transplant; 2010; 19(6):807-13. PubMed ID: 20573301 [TBL] [Abstract][Full Text] [Related]
15. Sustained and complete phenotype correction of hemophilia B mice following intramuscular injection of AAV1 serotype vectors. Chao H; Monahan PE; Liu Y; Samulski RJ; Walsh CE Mol Ther; 2001 Sep; 4(3):217-22. PubMed ID: 11545612 [TBL] [Abstract][Full Text] [Related]
16. In vivo response to vascular injury in the absence of factor IX: examination in factor IX knockout mice. Gui T; Reheman A; Funkhouser WK; Bellinger DA; Hagaman JR; Stafford DW; Monahan PE; Ni H Thromb Res; 2007; 121(2):225-34. PubMed ID: 17490728 [TBL] [Abstract][Full Text] [Related]
17. Titrating haemophilia B phenotypes using siRNA strategy: evidence that antithrombotic activity is separated from bleeding liability. Metzger JM; Tadin-Strapps M; Thankappan A; Strapps WR; DiPietro M; Leander K; Zhang Z; Shin MK; Levorse J; Desai K; Xu Y; Lai K; Wu W; Chen Z; Cai TQ; Jochnowitz N; Bentley R; Hoos L; Zhou Y; Sepp-Lorenzino L; Seiffert D; Andre P Thromb Haemost; 2015 Jun; 113(6):1300-11. PubMed ID: 25790442 [TBL] [Abstract][Full Text] [Related]
19. Structural analysis of factor IX protein variants to predict functional aberration causing haemophilia B. Mukherjee S; Saha A; Biswas P; Mandal C; Ray K Haemophilia; 2008 Sep; 14(5):1076-81. PubMed ID: 18540896 [TBL] [Abstract][Full Text] [Related]
20. Towards gene therapy for haemophilia B using primary human keratinocytes. Gerrard AJ; Hudson DL; Brownlee GG; Watt FM Nat Genet; 1993 Feb; 3(2):180-3. PubMed ID: 8499952 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]